Global Collaboration for Antibody Development
Harbour BioMed, a prominent biopharmaceutical company, has announced a significant collaboration with Bristol Myers Squibb aimed at discovering and developing next-generation multi-specific antibodies. This partnership promises to bring innovative therapeutic options in the fields of immunology and oncology.
Strategic Partnership Details
Under this new agreement, Harbour BioMed will work alongside Bristol Myers Squibb to enhance multi-specific antibody discovery initiatives. The partnership includes potential payments amounting to $90 million, in addition to development and commercial milestones that can exceed $1.035 billion, alongside tiered royalties if all programs are advanced by Bristol Myers Squibb.
CEO's Vision for Collaboration
Jingsong Wang, MD, PhD, who serves as the Founder, Chairman, and CEO of Harbour BioMed, expressed his enthusiasm, stating that this collaboration utilizes their Harbour Mice technology platform. This platform is designed for efficiently discovering and developing biologics, which are crucial for creating effective therapies. The unique capabilities of Harbour BioMed will allow the acceleration of early-stage clinical trials, particularly in markets such as China.
Innovative Technology at Core of Development
Harbour BioMed's proprietary antibody technology, known as Harbour Mice, enables the generation of fully human monoclonal antibodies in a versatile format comprising two heavy and two light chains (H2L2) and a heavy chain only (HCAb) format. These advanced antibodies support the creation of HCAb-based immune cell engagers (HBICE), which harbor the capability to deliver potent tumor-targeting effects that are often not achievable with conventional therapies.
Advantages of the Harbour Mice Platform
The integration of Harbour Mice with a single B cell cloning platform sets Harbour BioMed apart in the competitive landscape of antibody discovery. This advanced methodology not only streamlines the process of developing next-generation therapeutic antibodies but also ensures the development of targeted treatments that can significantly benefit patients.
About Harbour BioMed
Harbour BioMed is recognized for its commitment to pioneering novel antibody therapeutics, focusing on critical areas such as immunology and oncology. The company is continually enhancing its pipeline through a blend of robust research and development capabilities, collaborations with partners for co-discovery and co-development, and strategic acquisitions to solidify its position in the biopharmaceutical sector.
Frequently Asked Questions
What is the aim of the collaboration between Harbour BioMed and Bristol Myers Squibb?
The collaboration aims to discover and develop next-generation multi-specific antibodies that can advance treatments in immunology and oncology.
How much could Harbour BioMed receive from this partnership?
Harbour BioMed could potentially receive payments totaling $90 million, as well as up to $1.035 billion in additional milestones.
What technology does Harbour BioMed use in its antibody development?
Harbour BioMed utilizes the Harbour Mice technology platform for the efficient discovery and development of fully human monoclonal antibodies.
What are HCAb immune cell engagers?
HCAb immune cell engagers are bispecific antibodies capable of providing tumor-killing effects that traditional therapies cannot achieve.
What is Harbour BioMed's goal in the biotechnology industry?
The company's goal is to advance the development and commercialization of innovative antibody therapeutics to enhance patient outcomes in critical health areas.
